Goldman Sachs Beats the Drum on These 2 ‘Strong Buy' Stocks
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Driving this renewed optimism are several positive developments. President Trump's tariff policy appears to be bearing fruit, leading to new trade deals, while the one-and-done strike on Iran's nuclear program has helped ease tensions in the Middle East. Investors are also starting to discount the risk of a recession and are instead focusing on the prospect of additional interest-rate cuts in the second half of 2025. In this environment, strategists at Goldman Sachs see further room for the rally to continue, at least until August.
'We think this rally will continue for the next couple weeks but lose steam into August… We are entering the strongest month for the S&P historically July brings an average return of 1.67% looking back to 1928… In the recent rally, the ability to transfer risk quickly lends itself to healthier trading,' the Goldman strategists wrote.
Against this backdrop, Goldman's equity analysts are highlighting stocks they see as particularly well-positioned to benefit. Their latest focus is on two companies with very different profiles, each set to capitalize on the current bullish environment. This positive outlook is echoed by the broader market, as both names, according to TipRanks' database, also earn 'Strong Buy' ratings from the analyst consensus.
Goldman Sachs' latest stock picks include Ovintiv, an energy company operating across North America's key hydrocarbon basins. As an independent exploration and production (E&P) operator, Ovintiv manages a diverse portfolio of assets and plays an active role in the development of crude oil, natural gas, and natural gas liquids.
Ovintiv's main operations are located in three oil and gas basins, each well known in the North American energy industry. The firm's chief plays are in the rich Permian Basin of Texas, one of the largest oil deposits in the United States. The Permian is composed of multiple geological formations; Ovintiv's operations are focused on the Spraberry and Wolfcamp formations of the Midland Basin. One state over, Ovintiv is also working the Anadarko Basin in west-central Oklahoma, where the company's holdings target the SCOOP and STACK black oil windows. Finally, Ovintiv also works in the Canadian Rockies, in the Montney formation along the Alberta–British Columbia border. This is an unconventional oil and gas deposit and one of the largest on the continent. Ovintiv has a proven cube development approach that is particularly appropriate for extraction operations here.
We should note here that the Montney assets are a recent acquisition to Ovintiv's portfolio. The company closed on the purchase in January of this year, paying $2.3 billion in US currency for the new position. Ovintiv's purchase of Montney was conducted at the same time as its sale of its Uinta assets in northeastern Utah, for $2 billion in cash.
Ovintiv has a standing commitment to returning capital to its shareholders. The company has been generating positive free cash flow each year since 2018 and has returned an aggregate $2 billion to its shareholders. The capital returns are made through both dividends and share repurchases, although the share repurchase program was paused in 4Q24 and 1Q25 while the company balanced the costs of its Montney acquisition and Uinta divestiture. In 2Q25, Ovintiv resumed repurchases to the tune of approximately $146 million.
On the dividend, Ovintiv last declared the common share payment on May 6 and paid it out at a rate of 30 cents per share on June 30. At this rate, the dividend gives an annualized payment of $1.20 per common share and a forward yield of 3%.
During the first quarter of this year, the last period reported, Ovintiv reported a net loss of $159 million, which came to 61 cents per share. The company included a non-cash ceiling test impairment of $557 million, after taxes, in that figure. During the quarter, Ovintiv also generated a non-GAAP cash flow of $1.004 billion. After deducting $617 million in capital investments, the company had a non-GAAP free cash flow for the quarter of $387 million.
For Goldman analyst Neil Mehta, the key points here are Ovintiv's quality when compared to its peers and its recent streamlining of operations in shedding Uinta and adding Montney. In addition, the 5-star analyst goes on to point out Ovintiv's profitable exposure to natural gas.
'We believe the risk/reward to shares from current levels screens attractively relative to the larger cap diversified E&P peer group (EOG, OXY, DVN, CTRA, APA). Following OVV's divestiture of the higher-cost Uinta assets and the acquisition of deeper, more capital efficient Montney inventory, we believe that OVV's FCF generation trades at a meaningful discount relative to larger cap diversified E&P peers. As inventory quality and duration remain a key area of focus for E&P investors, we believe the Montney/Uinta transactions present a positive shift in the company's inventory position. In addition, we believe that the company's exposure to an inflection in natural gas prices remains underappreciated alongside our estimate of more upside relative to downside risk to Henry Hub commodity prices in the next 12-18 months as LNG export capacity ramps,' Mehta opined.
These bullish comments back up the analyst's Buy rating on OVV, while his $51 price target implies a one-year upside potential of ~28%. (To watch Mehta's track record, click here)
Overall, the Strong Buy consensus rating on Ovintiv is based on 16 recent analyst recommendations, which include 13 Buys and 3 Holds. The shares are priced at $39.92, and their $50.93 average target price is just below Goldman's estimate. (See OVV stock forecast)
Omada Health (OMDA)
The second stock on our list of Goldman Sachs picks, Omada Health, went public through an IPO just last month. Omada Health focuses on the care and control of chronic conditions, such as obesity, using online networking to connect patients with a monitoring team – including a personal health coach and a clinical specialist – to develop and carry out personalized care plans. The company's approach is centered on helping patients to make 'small and steady' health choices, which, taken together, will add up to large changes in lifestyle and overall health. Everything revolves around care plans that are tailored to individual patients and aim at managing or controlling conditions such as diabetes, obesity, high blood pressure, and chronic pain.
Omada has been at the forefront of virtual care in general health since 2011. The company's goal is to move patients past simply trying a new care program and help them to stick with it. Omada's solutions to this common problem in care and maintenance are evidence-based and have proven track records of success in helping patients to manage their chronic conditions and improve overall health.
As of this past March, Omada claims more than 1 million total all-time members enrolled in its programs, with over 679,000 currently enrolled. The company boasts that it has received customer satisfaction and customer retention rates of approximately 90%. In June of this year, the company announced that its GLP-1 companion program, used to promote patient compliance with GLP-1 weight-loss medications, had significantly improved persistence rates among patients, resulting in better weight-loss outcomes at both 12 and 24 weeks.
Stock in Omada, as noted above, hit the public markets in June of this year. The company priced its IPO at $19 per share, with trading in OMDA starting on June 6 and some 7.9 million shares being made available. The offering closed on June 9 and raised approximately $150 million in gross proceeds. OMDA shares closed at $23 on June 6, and the stock has declined by 23% since then.
Despite this initial pullback, Omada continues to attract the attention of analysts. David Roman covers this new stock for Goldman, and he is impressed by Omada's revenue growth in the past year, as well as by the company's potential for profitability in the near future.
'From 1H 2024 to 2H 2024, the company accelerated revenue growth from ~33% to ~43%, with 57% growth in 1Q 2025. The growth acceleration has been driven by underlying base growth, plus increase contribution from EncircleRx and GLP-1 program traction. Looking forward, we model the growth contribution of each of these moderating but momentum offers support for potential upside… We expect the company to reach break-even EBITDA in 3Q 2026 and profitability ($2 million) in 4Q 2026. This near-term path to profitability is largely supported by revenue scale, modest gross profit improvement and more material operating leverage (inclusive of incremental public company costs)… At current levels — considering the growth trajectory of the business, near-term path to profitability, and below peer valuation — we see OMDA offering compelling risk/reward,' Roman stated.
Quantifying his bullish stance, Roman sets a Buy rating on OMDA shares, along with a $29 price target that points to a ~56% potential gain in the year ahead. (To watch Roman's track record, click here)
What does the rest of the Street have to say? 7 Buys and no Holds or Sells add up to a Strong Buy consensus rating. The shares are trading for $18.63, and their $23.71 average price target indicates the stock may gain 27% by this time next year. (See OMDA stock forecast)
To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
42 minutes ago
- Miami Herald
Earnings season begins: Pay attention to all the tariff talk
The second-quarter earnings season is upon us: six weeks to eight weeks of numbers, not to mention company officials gloating or trying to defend their results against angry investors and analysts. This earning season, like the first-quarter season, will come with a big wildcard: President Donald Trump's efforts to impose much heavier tariffs on imports to the United States. Don't miss the move: Subscribe to TheStreet's free daily newsletter The Administration announced a huge list of tariffs increases on April 2 that shocked so many from the Federal Reserve to Wall Street that the Standard & Poor's 500 Index fell more than 10% over the next two days. Related: Analyst reboots Amazon stock price target on AI growth The president has proposed 35% tariffs on Canadian goods. And a 50% tariff on Brazil, the world's largest coffee producer (among other things) unless the Brazil halts prosecution of former Brazilian president Jair Bolsonaro, charging him with organizing a conspiracy to overturn Brazil's 2022 election. Over the weekend, Trump threatened 30% tariffs on Mexico and the European Union to take effect on Aug. 1 unless they come to a new deal. Related: Wall Street giant shares bold message on S&P 500's Magnificent 7 And we'll see, starting Sunday evening when futures trading begins at 6 p.m. ET, if investors force the administration to back down again. Tariffs are a dangerous game. You hear many Wall Streeters predicting the actual tariffs come in at roughly 10%. Trump learned a small lesson in April when stocks literally started to melt down. The history of draconian tariffs is they usually cause economic mayhem. And the politicians who get them enacted or their parties lose their jobs. So, in the meantime, the earnings start to come in: 103 in the week ahead and 702 in the week following. This week's reports are heavily weighted to financial institutions and big ones, too: JPMorgan Chase (JPM) , Wells Fargo (WFC) , BlackRock (BLK) and Citigroup (C) on of America (BAC) , Morgan Stanley (MS) and Goldman Sachs (GS) on Wednesday. American Express (AXP) and Charles Schwab (SCHW) on Friday. In all, some 42 financial companies will release reports this week. JPMorgan is the largest with a market cap of $797 billion. Among financial companies, only Berkshire Hathaway (BRK.A) and (BRK.B) is bigger at just over $1 trillion in market cap. (Yes, it's true Warren Buffett's conglomerate also includes one of the biggest railroads, See's Candies and a network of truck stops, but half the business is insurance. Berkshire is expected to report results in early August.) It's not all financial companies that report this week. Others include: United Airlines (UAL) on Semiconductor (TSM) , Netflix (NFLX) and PepsiCo (PEP) on Thursday. 3M Company (MMM) and Schlumberger (SLB) on Friday. Related: Stock Market Today: 35% Tariff on Canada Spooks Investors Financial institutions are always trying to balance interest on loans and earnings on investments against costs, especially cost of funds or, in the case of insurance companies, the costs of paying claims. The base short-term rate is the Fed's federal funds rate, now 4.25% to 4.5%. The Fed has been reluctant to cut rates this year because it's been concerned with how inflationary the tariffs will prove. Bloomberg/Getty Images The 73 financial stocks in the S&P 500 financial sector in the aggregate have had a decent year. The financial sector index is up 7.9% in 2025, with 48 stocks showing positive gains for the year to date. The return ranks the financials sixth out of the 11 S&P 500 sectors. Tops are the industrial and information technology sectors, up about 14% and 9.4%, respectively. The financial sector fell nearly 16% between April 2, when President announced his tariff proposal and the bottom of 702.44 on April 7. Since the bottom, the sector has rebounded about 24% to 868.31. The results are skewed a bit by Coinbase (COIN) , which runs one of the world's largest crypto currency exchanges. It's up 56% year to date. The company reports second-quarter earnings on July 31. More Investing: Weekly Wins: 10 Rules for You to Be a WinnerAmazon tries to make AI great again (or maybe for the first time)Veteran portfolio manager raises eyebrows with latest Meta Platforms moveGoogle plans major AI shift after Meta's surprising $14 billion move The big banks have not been scofflaws. Charles Schwab is up 22.3% year-to-date, second best in the sector. Citigroup has risen 23%. JP Morgan has added 19.7%. Goldman Sachs' gain is 23%. Related: Watch out: The threats that could derail the big rally Property-and-casualty insurance companies have struggled a bit this year, especially those exposed to the Los Angeles-area wild fires earlier this year. Chubb (CB) , Allstate (ALL) and Travelers (TRV) have seen their stocks show handsome returns over the last 52 weeks. But their returns for the year-to-date are flat or modest because of the fires. A study from UCLA estimated that the Los Angeles fires caused losses of between $95 billion and $164 billion with insured losses of some $75 billion. Wall Street is betting President Trump's big tax bill will unleash all sorts of money into the financial markets. That's why the S&P 500 and Nasdaq hit new highs this past week and Nvidia saw its market cap top $4 trillion. But forgotten in that euphoria was that financials were the weakest S&P 500 sector, down 1.9%. The bill, however, is so complicated that no one is sure what's in it, much less if the provisions will do any good. The banks and other financial companies will be getting looser regulations, true. But there's risk to that: Bad or just plain stupid actors can destabilize the system. Perhaps we should agree that a few signals would help. The economy has to demonstrate there's a clear, stable path forward. The Administration has to demonstrate clarity of vision. You don't want constant disruptions from tariffs or other political machinations. If the first condition is met, inflation can ease, and interest rates can come down. As important, companies will start to feel confident enough to expand new plants and offices and hire more people. Investment flows would migrate to opportunities that offer new growth. Related: Veteran analyst drops new clue on Nvidia's next big move The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
The Hill
an hour ago
- The Hill
‘One big beautiful bill,' and 4 Republicans who abandoned their principles
On July 4, amid fanfare and flyovers, President Trump signed his 'one big beautiful bill.' The legislation reduces taxes, increases appropriations for the military, border security and Immigration and Customs Enforcement — while cutting spending on Medicaid and the Supplemental Nutritional Assistance Program, better known as food stamps. According to the nonpartisan Congressional Budget Office, the bill's $4.5 trillion decrease in revenues and $1.2 trillion increase in spending will add $3.3 trillion over the next decade to the already astronomical $36 trillion national debt. Despite Trump's claims, the bill is extremely unpopular. Five recent polls found net approval ratings ranging from minus-19 percentage points to minus-29 points for the legislation. 'The more [Americans] learn about this bill, they hate it just as much,' declared Harry Enten, CNN's data analyst. Many Americans haven't yet realized that the tax cuts and estate tax changes, which disproportionately benefit the wealthy, have been made permanent, while the exemption on workers' tips and overtime and reductions on taxes to Social Security benefits will expire in 2028. Most are unaware that, in an attempt to minimize Republican losses in the midterms, legislators delayed until 2027 implementation of the Medicaid cuts (which will result in 11.8 million Americans losing their health insurance) and that reductions in the federal share of SNAP costs won't kick in until 2027. Opposition from so-called Republican 'moderates' and 'deficit hawks' initially appeared sufficient to defeat or at least force substantial revisions of the bill. But virtually all of them caved. For once, Elon Musk had it right. The 'big beautiful bill,' Musk wrote, is a 'disgusting abomination. Shame on those who voted for it. You know you did wrong. You know it.' Here are profiles of four Republicans who shelved their principles. Rep. David Valadao (R-Calif.), whose district contains one of the nation's highest percentages of Medicaid recipients, stated unequivocally that he would not support legislation 'that includes any reduction in Medicaid coverage for vulnerable populations.' Nonetheless, he voted for the House bill. Valadao then expressed concerns about changes in the Senate: 'I've been clear from the start that I will not support a final reconciliation bill that makes harmful cuts to Medicaid, puts critical funding at risk, or threatens the stability of healthcare providers.' Although the Senate reduced Medicaid appropriations by almost a trillion dollars and cut almost in half the tax states can impose on private healthcare providers, a 'vital stream' of income for the program, Valadao voted for the final bill. It 'was not an easy decision,' Valadao said, but 'no piece of legislation is perfect.' The Senate bill, he claimed, 'does preserve the program for its intended recipients — children, pregnant women, the disabled and elderly.' And it included a fund to give rural hospitals a few years to adjust to reduced revenues. Going forward, Valadao promised to work hard to identify and mitigate risks. In December 2024, Rep. Chip Roy (R-Texas) did not accede to President-Elect Trump's demand that Republicans raise the debt ceiling by $5 trillion dollars. 'I'm absolutely sickened,' he proclaimed, 'by a party that campaigned on fiscal responsibility and has the temerity to go forward to the American people and say you think this is fiscally responsible.' This spring, however, Roy voted for the reconciliation bill, which included that $5 trillion increase in the debt ceiling and added trillions to the deficit, after Speaker Mike Johnson (R-La.) agreed to advance implementation of the work requirement in Medicaid from 2029 to 2026. 'Mediocre but passable,' he said, the bill still needed 'massive improvements if we are to make a dent in our deficit or to change the trajectory of this country.' The Senate 'failed us,' Roy claimed. We can 'amend it, send it back, fix it … Happy to stay here every day until we get it right.' Yet within days, Roy announced he was convinced the Trump administration would use executive orders and other legislation 'to ameliorate those areas' made worse by the Senate — and voted for the final bill. Asked about Musk's characterization of the House bill, Sen Ron Johnson (R-Wis.) replied, 'He's telling the truth.' The legislation doesn't 'bend the deficit curve down. It supports it going up.' Johnson indicated 'there's no way' he would support a bill that sustained this 'new normal.' He was untroubled by the president's threat that anyone who opposed his bill would face a primary challenge: 'I'd be happy to be done with politics.' After meeting with Trump and members of his staff, however, Johnson indicated he was satisfied they were 'committed' to reducing federal spending to pre-pandemic levels: 'A rigorous effort will soon be announced,' he added, 'to review every program and every line of the federal budget, looking for ways to… put America on the path to fiscal sustainability.' Johnson voted for a Senate bill that added about a trillion dollars more to the national debt than the House bill. After the Senate passed Trump's bill, a reporter asked Sen. Lisa Murkowski (R-Alaska) about the assertion by Sen. Rand Paul (R-Ky.) that instead of joining him, Sen. Thom Tillis (R-N.C.) and Sen. Susan Collins (R-Maine) to defeat the legislation, she engineered 'a bailout for Alaska at the expense of the rest of the rest of the country.' After a long pause, Murkowski, who had 'made very clear' in June that 'we cannot go forward with a bill that makes cuts to Medicare,' replied, 'I know that in many parts of the country there are Americans that are not going to be advantaged by this bill … But when I saw the direction that this is going — you know you can either say, 'I don't like it' and not try to help my state, or you can roll up your sleeves.' Murkowski used her leverage to delay the requirement that states with high food stamp error rates, including Alaska, contribute more to the cost of benefits. Alaska and Hawaii received waivers of food stamp work requirements based on high unemployment rates in their states. And the bill provided tax relief for whaling boat captains. 'This has been an awful process,' Murkowski explained, 'a frantic race to meet an artificial deadline.' As the legislation returned to the House, she expressed her 'sincere hope that this is not the final product.' While she had made improvements for Alaska, this bill 'is not good enough for the rest of the nation — and we all know it.' It 'needs more work across chambers and is not ready for the president's desk.' In the months before the 2026 elections, Democrats will almost certainly be quoting Valadao, Roy, Johnson and Murkowski, and making the point that promises by allegedly principled Republican politicians are nothing but 'sound and fury, signifying nothing.' Glenn C. Altschuler is the Thomas and Dorothy Litwin Emeritus Professor of American Studies at Cornell University.
Axios
an hour ago
- Axios
Federal workers face mass firings this summer after Supreme Court ruling
It's shaping up to be a summer of firings for tens of thousands of federal workers, now that the Supreme Court cleared the way for agencies to conduct layoffs. Why it matters: Opponents of the White House chainsaw approach say the federal government's capabilities will be forever damaged by these cuts. The Trump administration says this is just a step toward better government efficiency. Zoom out: For these workers, the timing of these cuts— known as reductions in force, or RIFs in fed-speak — is particularly bad. The hiring market is bleak for those who are out of work and looking for jobs, federal data shows. Catch-up quick: Thousands of workers across 19 agencies, who received notice that they were being fired back in the spring, have been out on paid leave pending the results of the court challenge to their dismissals. The Supreme Court lifted a stay on their firings this week. Now these workers are just waiting for the axe to fall — again. "It's not waiting to hear 'if,' it's waiting to hear [when]," says Aisha Coffey, a strategic communications specialist at the FDA, who got a separation letter from the agency in April. Coffey is somewhat sure that at least her next paycheck will be coming, as the most recent pay period ended on Friday. Overall the past few months has felt like "government Squid Games," she says, referencing the dystopian Netflix series where contestants battle to the death. An IRS employee tells Axios on Friday, "we're just waiting for the guillotine." Where it stands: The State Department got moving on RIFs Friday, only days after the Supreme Court ruling. A cable from Secretary of State Marco Rubio, reviewed by Axios, went out across the agency on Friday announcing a reorganization that would lead to 3,000 departures. That includes layoffs of 1,353 employees — 1,107 in civil service and 246 in foreign service. The remaining departures were through the deferred resignation program, per an agency official. The State Department had no further comment, but White House spokeswoman Anna Kelly said: "Bloated operations often result in duplicative or even contradictory foreign policy. By reorganizing the Department of State, Secretary Rubio is ensuring that all actions align with the America First agenda that people voted for." Reality check: It's not clear yet how manny agencies will follow through with their RIF plans, notes the Washington Post. Some have dialed back plans. And the Supreme Court didn't actually rule on the merits of these actions in its decision this week — the case is still moving forward. The bottom line: Even if workers eventually prevail, the fact that firings can now proceed, and are happening, will lead to huge changes in how the government works (or doesn't). The damage is done, says Erik Snyder, a counsel at Gilbert Employment Law, who represented the RIFd workers in the case decided this week.
